Tuning, Rather than Blocking, Immunity in IBD

About this episode

Marc de Garidel discusses how Abivax is innovating treatment for inflammatory bowel disease by fine-tuning the immune system.

The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting that fine-tuning, rather than suppressing, the immune system can reshape the treatment paradigm in IBD. Marc de Garidel, CEO of Abivax, discusses how a once-failed HIV candidate evolved into a late‑stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but still underserved IBD market.

People in this episode

Guest: Marc de Garidel

Topics covered

• immunology
• inflammatory bowel disease
• treatment innovation
• healthcare
• biotechnology

Keywords

• inflammatory bowel disease
• immunosuppressive therapies
• immune system
• treatment paradigm
• durable remission

Mentioned in this episode

Organizations: Abivax

Books & works: HIV candidate

Places: IBD

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
• Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min